Universal Beteiligungs und Servicegesellschaft mbH Increases Stock Position in CVS Health Corporation $CVS

Universal Beteiligungs und Servicegesellschaft mbH lifted its holdings in CVS Health Corporation (NYSE:CVS) by 14.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 810,150 shares of the pharmacy operator’s stock after acquiring an additional 101,671 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.06% of CVS Health worth $55,884,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in CVS. Avion Wealth increased its stake in CVS Health by 99.0% during the 2nd quarter. Avion Wealth now owns 380 shares of the pharmacy operator’s stock worth $26,000 after buying an additional 189 shares during the period. Harbor Asset Planning Inc. purchased a new stake in shares of CVS Health during the second quarter worth about $30,000. Bell Investment Advisors Inc lifted its stake in shares of CVS Health by 119.8% in the first quarter. Bell Investment Advisors Inc now owns 455 shares of the pharmacy operator’s stock worth $31,000 after acquiring an additional 248 shares in the last quarter. Roxbury Financial LLC boosted its holdings in CVS Health by 78.3% in the second quarter. Roxbury Financial LLC now owns 460 shares of the pharmacy operator’s stock valued at $32,000 after purchasing an additional 202 shares during the last quarter. Finally, ORG Partners LLC grew its stake in CVS Health by 418.9% during the 2nd quarter. ORG Partners LLC now owns 467 shares of the pharmacy operator’s stock valued at $32,000 after purchasing an additional 377 shares in the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

CVS Health Stock Performance

NYSE:CVS traded up $1.58 during mid-day trading on Monday, hitting $79.39. The stock had a trading volume of 310,729 shares, compared to its average volume of 9,139,579. CVS Health Corporation has a 52 week low of $43.56 and a 52 week high of $85.15. The stock has a market capitalization of $100.77 billion, a price-to-earnings ratio of 208.56, a P/E/G ratio of 0.87 and a beta of 0.60. The company has a 50 day simple moving average of $77.70 and a 200-day simple moving average of $69.96. The company has a current ratio of 0.83, a quick ratio of 0.62 and a debt-to-equity ratio of 0.83.

CVS Health (NYSE:CVS) last posted its earnings results on Wednesday, October 29th. The pharmacy operator reported $1.60 EPS for the quarter, beating the consensus estimate of $1.36 by $0.24. CVS Health had a return on equity of 11.45% and a net margin of 0.12%.The firm had revenue of $102.87 billion for the quarter, compared to analysts’ expectations of $98.85 billion. During the same period last year, the firm earned $1.09 EPS. The firm’s revenue was up 7.8% compared to the same quarter last year. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. On average, research analysts expect that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, November 3rd. Investors of record on Thursday, October 23rd were paid a dividend of $0.665 per share. The ex-dividend date of this dividend was Thursday, October 23rd. This represents a $2.66 annualized dividend and a yield of 3.4%. CVS Health’s dividend payout ratio (DPR) is currently 700.00%.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on CVS shares. Sanford C. Bernstein upped their target price on CVS Health from $72.00 to $77.00 and gave the company a “market perform” rating in a research report on Friday, September 5th. Royal Bank Of Canada upped their price target on shares of CVS Health from $81.00 to $93.00 and gave the company an “outperform” rating in a report on Thursday, October 30th. UBS Group increased their price objective on shares of CVS Health from $79.00 to $96.00 and gave the company a “buy” rating in a research note on Friday, October 24th. Morgan Stanley boosted their target price on shares of CVS Health from $82.00 to $89.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 14th. Finally, TD Cowen increased their price target on shares of CVS Health from $99.00 to $100.00 and gave the stock a “buy” rating in a research report on Monday, November 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $89.41.

Insider Activity

In related news, Director Anne A. Finucane sold 7,500 shares of the business’s stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $71.02, for a total value of $532,650.00. Following the sale, the director directly owned 22,156 shares in the company, valued at $1,573,519.12. The trade was a 25.29% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.22% of the stock is owned by corporate insiders.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.